Thoracic (Lung) Cancer Trial

Non-Small Cell, Advanced

Firstline Pembrolizumab Alone or in Combination with Pemetrexed and Carboplatin in Induction / Maintenance or Postprogression in Treating Patients with Stage IV Non-squamous Non-small Cell Lung Cancer

OR

INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination
with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous
Non-Small Cell Lung Cancer with Immunobiomarker SIGNature-driven Analysis

 

Physician and Research Staff Educational Material

This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.

    • Pocket Reference Card: trial schema, study objectives, and eligibility requirements on a pocket-sized card for easy reference when consulting with patients in the office or on rounds.
    • Physician Fact Sheet: schema, study objectives, eligibility criteria, and other key information about the study.

Information and Assistance from the National Cancer Institute

    • Locations and other information
    • Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail.

ClinicalTrials.gov ID: NCT03793179

Return to Home Page | Review Other Active Trials